Chemotherapy-Induced Peripheral NeuropathyMarch 15th 2016
Chemotherapy-induced peripheral neuropathy (CIPN) is a common treatment-related side effect of several widely used drugs. Agents known to cause CIPN include platinum analogs, antitubulins, proteasome inhibitors, immunomodulatory agents, and some of the newer biologics.
Vaccine Therapies Against Gliomas: Prime Time Yet?March 15th 2016
The promise of vaccine-based anticancer therapies has been explored for a number of years. However, the research met with little success in its early phases, largely because of a poor understanding of the biology of the immune system and its role in combatting cancer.
More Opaque Than Clear: Reality Is Always Cloaked in Shades of GrayMarch 15th 2016
Lung cancer exhibits a wide spectrum of behavior, from inconsequential to nonaggressive, typically aggressive, and very aggressive lung cancer. The proportion of “well-behaved” cancers has clearly been increased by the advent of CT screening.
Vincent T. DeVita on His New Book, “The Death of Cancer,” and the Current State of Cancer CareMarch 15th 2016
The mandate of the National Cancer Act of 1971 was “to support research and the application of the results of research, to reduce the incidence, morbidity, and mortality from cancer,” and we have done that.
HPV and Penile Cancer: Perspectives on the Future Management of HPV-Positive DiseaseMarch 15th 2016
Over the past 5 years, several studies have investigated the molecular profiling of penile carcinomas, examining both genomic and epigenetic alterations. These studies have revealed distinct molecular pathways associated with HPV status.
The Quest for an Evidence-Based Approach to Intermediate-Risk Prostate CancerMarch 15th 2016
We must now come to a uniform consensus regarding the descriptions of these risk groups in order to truly determine which treatments have the best oncologic efficacy, while minimizing overtreatment and optimizing patients’ quality of life.